Tofacitinib or adalimumab versus placebo in rheumatoid arthritis

New England Journal of Medicine

Volumn 367, Issue 6, 2012, Pages 508-519

  Van Vollenhoven, Ronald F ^a   Fleischmann, Roy ^b   Cohen, Stanley ^b   Lee, Eun Bong ^c   Meijide, Juan A García ^d   Wagner, Sylke ^e,f   Forejtova, Sarka ^g   Zwillich, Samuel H ^h   Gruben, David ^h   Koncz, Tamas ^h   Wallenstein, Gene V ^h   Krishnaswami, Sriram ^h   Bradley, John D ^h   Wilkinson, Bethanie ^h  

^a KAROLINSKA INSTITUTE   (Sweden)

^b METROPLEX CLINICAL RESEARCH CENTER   (United States)

^c Seoul National University   (South Korea)

^d HOSPITAL DE L ESPERANÇA   (Spain)

^e Internistische Schwerpunktpraxis für Rheumatologie   (Germany)

^f UNIVERSITY OF LEIPZIG   (Germany)

^g INSTITUTE OF RHEUMATOLOGY   (Czech Republic)

^h PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; METHOTREXATE; PLACEBO; TOFACITINIB;

ABDOMINAL WALL HERNIA; ACUTE CHOLECYSTITIS; ACUTE HEART INFARCTION; ANUS POLYP; ARTICLE; AUTOIMMUNE THYROIDITIS; BLOOD DISEASE; BONE MARROW DEPRESSION; BREAST ABSCESS; BURSITIS; CELLULITIS; CHOLECYSTITIS; CHOLELITHIASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPLETE HEART BLOCK; CONGESTIVE HEART FAILURE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE DURATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EAR DISEASE; EMPYEMA; ENDOCRINE DISEASE; ERYSIPELAS; ERYTHROCYTE SEDIMENTATION RATE; EYE DISEASE; FEMUR FRACTURE; FEVER; FIBULA FRACTURE; GALLBLADDER EMPYEMA; GASTROENTERITIS; GASTROINTESTINAL DISEASE; GENITAL SYSTEM DISEASE; HEALTH ASSESSMENT QUESTIONNAIRE; HEARING IMPAIRMENT; HEART ARREST; HEART DISEASE; HEART MUSCLE ISCHEMIA; HEMATEMESIS; HEPATOBILIARY DISEASE; HERPES ZOSTER; HUMAN; HUMERUS FRACTURE; ILEUS; IMMUNE RESPONSE; IMMUNOMODULATION; INNER EAR DISEASE; INTERSTITIAL LUNG DISEASE; INTESTINE PERFORATION; JOINT DISLOCATION; LIMB FRACTURE; LIVER DISEASE; LUNG ABSCESS; LUNG NON SMALL CELL CANCER; LUNG SARCOIDOSIS; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MELENA; METABOLIC DISORDER; METRORRHAGIA; MUSCULOSKELETAL DISEASE; NEUROMA; NEUTROPENIA; NUTRITIONAL DISORDER; OSTEOMYELITIS; OUTCOME ASSESSMENT; OVARY CYST; OVARY INFLAMMATION; OVARY TORSION; PEPTIC ULCER BLEEDING; PHASE 3 CLINICAL TRIAL; PNEUMONIA; POLYP; PRIORITY JOURNAL; PRURIGO; RANDOMIZED CONTROLLED TRIAL; RETINA DETACHMENT; RHEUMATOID ARTHRITIS; SALIVARY GLAND CALCULUS; SALIVARY GLAND DISEASE; SEPTIC SHOCK; SIALOADENITIS; SIDE EFFECT; SPONDYLOLISTHESIS; TENDON DISEASE; TENDON RUPTURE; THORAX PAIN; TIBIA FRACTURE; UTERINE CERVIX DISEASE; VASCULAR DISEASE; VERTIGO;

EID: 84864703156     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1112072     Document Type: Article

References (18)

1. Strand V, Singh JA. Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. Am J Manag Care 2007;13:Suppl 9:S237-S251.
2. Hochberg MC, Johnston SS, John AK. The incidence and prevalence of extra-articular and systemic manifestations in a cohort of newly-diagnosed patients with rheumatoid arthritis between 1999 and 2006. Curr Med Res Opin 2008;24:469-80. (Pubitemid 351294396)
3. Breedveld F. The value of early intervention in RA - a window of opportunity. Clin Rheumatol 2011;30:Suppl 1:S33-S39.
4. O'Dell JR. Therapeutic strategies for rheumatoid arthritis. N Engl J Med 2004;350:2591-602.
5. Bathon JM, Cohen SB. The 2008 American College of Rheumatology recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: where the rubber meets the road. Arthritis Rheum 2008;59:757-9. (Pubitemid 351847557)
6. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762-84. (Pubitemid 351847559)
7. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75. [Erratum, Ann Rheum Dis 2011;70:1519.]
8. Flanagan ME, Blumenkopf TA, Brissette WH, et al. Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. J Med Chem 2010;53:8468-84.
9. Meyer DM, Jesson MI, Li X, et al. Antiinflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm (Lond) 2010;7:41.
10. Sewgobind VD, Quaedackers ME, van der Laan LJ, et al. The Jak inhibitor CP-690,550 preserves the function of CD4CD25FoxP3 regulatory T cells and inhibits effector T cells. Am J Transplant 2010;10:1785-95.
11. Ghoreschi K, Jesson MI, Li X, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol 2011;186:4234-43.
12. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. (Pubitemid 18091653)
13. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology: preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
14. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45. (Pubitemid 10164318)
15. Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol 2005;23: Suppl:S93-S99. (Pubitemid 46657516)
16. Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012;367:495-507.
17. Simon TA, Smitten AL, Franklin J, et al. Malignancies in the rheumatoid arthritis abatacept clinical development program: an epidemiological assessment. Ann Rheum Dis 2009;68:1819-26.
18. Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large United States observational study. Arthritis Rheum 2007;56:2886-95. (Pubitemid 47502734)